TABLE 3.

Predicted and observed changes in oral midazolam (2.5 mg) pharmacokinetics after chronic (1 g thrice daily for 6 days) or acute (a single 3-g dose) goldenseal administration

Data represent geometric means [90% confidence intervals]. Ratios denote the AUC_0–12h or C_max of midazolam in the presence to absence of goldenseal.

	Observed	Predicted	Predicted/Observed
Midazolam Pharmacokinetics
Chronic Goldenseal Exposure
AUC0–12h ratio	1.39 [1.30–1.48]	1.49 [1.46–1.53]	1.07
Cmax ratio	1.31 [1.16–1.48]	1.43 [1.40–1.47]	1.10
Acute Goldenseal Exposure
AUC0–12h ratio	1.57 [1.39–1.77]	1.28 [1.27–1.30]	0.82
Cmax ratio	1.40 [1.12–1.74]	1.26 [1.24–1.27]	0.90